Clinical and Virologic Response to HHV-8 Associated Multicentric Castleman's Disease to Valganciclovir.

Trial Profile

Clinical and Virologic Response to HHV-8 Associated Multicentric Castleman's Disease to Valganciclovir.

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Valganciclovir (Primary)
  • Indications Giant lymph node hyperplasia
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Jun 2009 Planned end date (May 2009) added as reported by ClinicalTrials.gov.
    • 09 Feb 2009 Planned number of patients changed from 64 to 8 as reported by ClinicalTrials.gov.
    • 09 Feb 2009 Actual initiation date (Dec 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top